The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
90 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $39,227,339 in first-year total cost, median $260,664.
Most frequent study sections
- Special Emphasis Panel[ZDA1 GXM-A (03)]25
- Special Emphasis Panel[ZDA1 GXM-A (02)]18
- Special Emphasis Panel[ZDA1 GXM-A (01)]13
- Special Emphasis Panel[ZDA1 GXM-A (15)]13
- Special Emphasis Panel[ZDA1 GXM-A (24)]12
Most frequent institutions
- CLEAR SCIENTIFIC, LLC3
- SPARK BIOMEDICAL INC3
- AYUDA MEDICAL2
- BDH PHARMA, LLC2
- CREATIVE BIO-PEPTIDES, INC.2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.2R44DA050358-02A1 | SCHIFFER, FREDRICTEICHER, MARTIN H | MINDLIGHT, LLC, MA | $1,519,167 | ZDA1 |
| 2022 | Abuse-deterrence and prevention of respiratory depression by an oral opioid analgesic and doxapram combination1R44DA055336-01 | RIX, PETER JEFFREYSESSLER, DANIEL I | QUIVIVE PHARMA, INC, CA | $1,393,153 | ZDA1 |
| 2022 | Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.2R44DA049615-02A1 | AL FARUQUE, MOHAMMAD ABDULLAHSHARAREH, SHIVATSENG, PETER | REKOVAR INC., CA | $1,215,174 | ZDA1 |
| 2022 | A Naloxone Parachute: Novel Wearable Dual-Sensor Regional Oximeter to Detect Opioid-Induced Hypoxia and Enable Emergent Naloxone Rescue2R44DA051257-02 | HITE, DESISLAVA ZLATANOVA | AYUDA MEDICAL, WA | $911,396 | ZDA1 |
| 2022 | Rapid Assessment of Illicit Drugs in Wastewater2R44DA051105-02 | ARGUN, AVNI A | GINER, INC., MA | $849,128 | ZDA1 |
| 2022 | Wearable sensor for opioids detection based on electrochemical sensor arrayintegrated with Bluetooth device2R44DA051289-02 | LEVITSKY, IGOR A | EMITECH, INC., MA | $775,215 | ZDA1 |
| 2022 | Evaluation of a Mobile Application for Patients and Clinical Decision-making Support Tools for Prescribers to Decrease Opioid Misuse and Habit-forming Behaviors Following Post-operative Prescription1R44DA055408-01 | WALTHER, STEVEN | CONTINUOUS PRECISION MEDICINE, INC., NC | $762,017 | ZDA1 |
| 2022 | Reducing Opioid Use and Adverse Effects through Proactive Precision Pain Management Following Spine Surgery1R44DA056280-01 | PLUMP, STEVEN R.SADHASIVAM, SENTHILKUMAR | OPALGENIX, INC., IN | $326,500 | ZDA1 |
| 2022 | Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.1R44DA056267-01 | TORRALVA, PHILLIP RANDOLPH | TORRALVA MEDICAL THERAPEUTICS, LLC, OR | $324,196 | ZDA1 |
| 2022 | User-centric development of closed-loop therapy for opioid overdose1R44DA056277-01 | LE, VYLEE, HYOWON | RESCUE BIOMEDICAL, LLC, IN | $319,995 | ZDA1 |
| 2022 | A novel therapeutic approach for treatment of acute intoxication by co-use of opioids and stimulants1R43DA056272-01 | LI, XINHUA | CLEAR SCIENTIFIC, LLC, MA | $319,695 | ZDA1 |
| 2022 | Development and Commercialization of a pupillometer to predict postoperative opioid-induced respiratory depression in children1R44DA055407-01 | OLIVER, JEFFREY WADEPRIVITERA, CLAUDIOSADHASIVAM, SENTHILKUMAR | NEUROPTICS, INC., CA | $319,082 | ZDA1 |
| 2022 | Remotely Observed Methadone Evaluation (ROME)1R43DA056259-01 | BAILEY, STEFFANI RGILES, MICHAEL | SONARA HEALTH INC, TX | $267,861 | ZDA1 |
| 2022 | Fast-track: Scalable digital delivery of evidence-based training for addiction professionals to maximize treatment admission and retention rates of opioid use disorder in affected families.1R44DA053845-01A1 | MACKY, JANE | WE THE VILLAGE, INC., NY | $259,585 | ZDA1 |
| 2022 | New therapeutic approaches to identifying molecules for opioid abuse treatment1R43DA055419-01 | EKINS, SEAN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $256,220 | ZDA1 |
| 2022 | Identification of Cyclic Peptide Antagonists of an Anti-Opioid G Protein-Coupled Receptor1R43DA053844-01 | LABED, SID AHMED | EVODENOVO, INC., MA | $255,061 | ZDA1 |
| 2022 | Modeling Physiology and Behavior of Veterans to Avert Opioid Related Mortality Through Timely Intervention1R44DA053874-01A1 | FORMAN, STEVEN D.FORSTER, SARAH EGORDON, ELLIE | BEHAIVIOR, LLC, PA | $253,479 | ZDA1 |
| 2022 | Digital Peer Support for Opioid Use Disorders: Scaling Chat Support Groups to meet Community Needs1R43DA056275-01 | BOMMARAJU, SATYA PRATEEK | BEACON TECH, INC., MA | $252,131 | ZDA1 |
| 2022 | Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.1R44DA056251-01 | NORBECK, AMBER | OPIO CONNECT, INC., MT | $156,220 | ZDA1 |
| 2021 | Prapela™ SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.2R44DA049300-02 | KONSIN, JOHN PHILLIPSINGH, RACHANA | PRAPELA, INC., ME | $1,330,596 | ZDA1 |
| 2021 | Novel Therapeutic Agents to Reverse Opioid Overdose2R44DA052957-02 | LI, XINHUA | CLEAR SCIENTIFIC, LLC, MA | $1,283,728 | ZDA1 |
| 2021 | Delivering Transcutaneous Auricular Neurostimulation as an Adjunct Treatment for Neonatal Opioid Withdrawal Syndrome2R44DA050360-02 | JENKINS, DOROTHEA DENISEKHODAPARAST, NAVID | SPARK BIOMEDICAL INC, TX | $1,249,662 | ZDA1 |
| 2021 | Delivering Transcutaneous Auricular Neurostimulation to Improve Treatment Retention in Opioid Use Disorder1R44DA053876-01 | KHODAPARAST, NAVID | SPARK BIOMEDICAL INC, TX | $1,246,700 | ZDA1 |
| 2021 | Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder2R44DA050349-02 | RUFF, MICHAEL R | CREATIVE BIO-PEPTIDES, INC., MD | $1,151,331 | ZDA1 |
| 2021 | Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose.2R44DA050397-02 | BRIONES, MARISA | BDH PHARMA, LLC, CA | $973,920 | ZDA1 |
| 2021 | Transcranial ultrasound device for enhancing sleep in OUD1R43DA055399-01 | MAHADEVAN, RAJIV | ATTUNE NEUROSCIENCES, INC., CA | $319,441 | ZDA1 |
| 2021 | Development of CP-analogs as novel treatments for opioid use disorder.1R44DA053846-01 | REICH, JEFFREY | SPARIAN BIOSCIENCES, INC., NY | $319,223 | ZDA1 |
| 2021 | Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder1R44DA053848-01 | WEISBERG, RISA B | BEHAVR, LLC, KY | $319,021 | ZDA1 |
| 2021 | DEVELOPMENT OF A FULLY-INTEGRATED CHATBOT TO IMPROVE MEMBER ENGAGEMENT IN ONLINE ADDICTION TREATMENT PROGRAMS1R44DA054010-01 | MCINTOSH, ROBIN | WORKIT HEALTH, INC., MI | $314,004 | ZDA1 |
| 2021 | Network Synchrony Neurofeedback for Opioid Dependence1R43DA052945-01A1 | FEIN, GEORGE | NEUROBEHAVIORAL RESEARCH, INC., HI | $269,320 | ZDA1 |
| 2021 | Incentivized Collaborative Care to Desseminate Contingency Management1R44DA055396-01 | DEFULIO, ANTHONYGASTFRIEND, DAVID R | DYNAMICARE HEALTH, INC., MA | $255,071 | ZDA1 |
| 2021 | Using Augmented Reality illusion therapy to develop a non-opioid chronic pain digital treatment1R43DA053048-01 | LAFFERTY, PAUL | VRX MEDICAL INC., CA | $250,616 | ZDA1 |
| 2021 | BoostOne1R43DA051270-01A1 | PATEL, SALIL | NXTECH INC, TX | $245,648 | ZDA1 |
| 2021 | Opioid Support and Risk Reduction Online Platform1R43DA049606-01A1 | GARETT, RENEE | ELEVATEU, CA | $238,994 | ZDA1 |
| 2021 | On Demand Electrostimulation1R43DA055401-01 | LEVIN, HOWARD | CORIDEA, LLC, NY | $223,921 | ZDA1 |
| 2021 | Technologies for OUD Prevention, Control and Supportive Care - Development of Patient/Caregiver mobile application and Provider Dashboard1R43DA053870-01 | ELUMALAI, SATHYA | AIDAR HEALTH, INC, MD | $221,150 | ZDA1 |
| 2020 | BioMote for Opioid Use Disorder (OUD) Recovery2R44DA044905-02 | SCHMIDLE, PATRIK | CARI HEALTH, INC., CA | $1,781,902 | ZDA1 |
| 2020 | Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for Opioid Use Disorder2R44DA049616-02 | NWULIA, EVARISTUS ASETH, SUMEET | EVON MEDICS, LLC, MD | $820,883 | ZDA1 |
| 2020 | A patient self-assessment software combining compliance protocols to improve prescriber confidence, reduce liability, and improve patient outcomes.1R44DA051272-01 | HARTZEMA, ABRAHAM G | CLARITY, LLC, AL | $722,339 | ZDA1 |
| 2020 | Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder1R43DA053010-01 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $349,967 | ZDA1 |
| 2020 | Wearable Device for Prevention of Opioid-Induced Respiratory Depression, Hypoxemia and Death1R43DA050336-01A1 | OLSON, LLOYD | LLOYD OLSON, MD, LLC, CO | $349,336 | ZDA1 |
| 2020 | Wearable Device for Automatic Delivery of Naloxone during Respiratory Arrest due to Opioid Overdose1R43DA049622-01 | VAZIRI, ASHKAN | BIOSENSICS, LLC, MA | $348,832 | ZDA1 |
| 2020 | A Naloxone Parachute: Novel Wearable Dual-Sensor Regional Oximeter to Detect Opioid-Induced Hypoxia and Enable Emergent Naloxone Rescue1R43DA051257-01A1 | HITE, DESISLAVA ZLATANOVA | AYUDA MEDICAL, WA | $338,084 | ZDA1 |
| 2020 | Deep Brain Stimulation Probe Insertion System Utilizing Ultrasonic Vibration for Less Invasive Implantation with Improved Targeting Accuracy for Addiction Therapy1R43DA051265-01 | CLEMENT, RYAN S | ACTUATED MEDICAL, INC., PA | $333,133 | ZDA1 |
| 2020 | "Wearable sensor for opioids detection based on electrochemical sensor array integrated with Bluetooth device "1R43DA051289-01A1 | LEVITSKY, IGOR A | EMITECH, INC., MA | $328,961 | ZDA1 |
| 2020 | Development of a novel translational pain-drug screening platform for the generation of human-relevant data in preclinical pain drug discovery1R43DA052947-01 | GHETTI, ANDREA | ANABIOS CORPORATION, CA | $320,054 | ZDA1 |
| 2020 | PROCare: Cloud Process Support for Opioid Recovery Participation and Learning1R43DA051298-01A1 | PROCTOR, STEVENTIEN, ALLEN Y. | MEDICAL DECISION LOGIC, INC., MD | $290,832 | ZDA1 |
| 2020 | A Fentanyl Vaccine to Prevent Overdose1R43DA052960-01 | VERDI, JOSEPH P | HEPIONE THERAPEUTICS INC., NY | $261,742 | ZDA1 |
| 2020 | Fathering in Recovery1R43DA052949-01 | JONES, JEREMY AUSTIN | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $256,521 | ZDA1 |
| 2020 | Longer-acting intravaginal formulation of buprenorphine1R44DA053073-01 | SMITH, THOMAS J. | AURITEC PHARMACEUTICALS, INC., CA | $253,692 | ZDA1 |
| 2020 | ProGel Technology for Better Management of Osteoarthritis Pain1R44DA051278-01 | GOLDRING, STEVEN | ENSIGN PHARMACEUTICAL, INC, NE | $252,131 | ZDA1 |
| 2020 | Leveraging Roundtrip, the single touchpoint for medical transportation, to eliminate transportation as a barrier to care for specialized patient populations such as those with opioid use disorder.1R43DA051263-01 | MCNIFF, BRENDAN | RIDE ROUNDTRIP, INC., PA | $252,131 | ZDA1 |
| 2020 | Rapid and non-invasive device for drug detection through sweat1R43DA052941-01 | KULKARNI, GIRISH | ARBORSENSE, INC., MI | $252,062 | ZDA1 |
| 2020 | A Chatbot Utilizing Machine Learning and Natural Language Processing to Implement the Brief Negotiation Interview to Improve Engagement in Buprenorphine Treatment among Justice-Involved Individuals1R43DA051267-01A1 | PANTALON, MARIANNE SHARSKYPANTALON, MICHAEL V | CENTER FOR PROGRESSIVE RECOVERY, LLC, CT | $251,500 | ZDA1 |
| 2020 | Project Motivate: A digital motivation and prediction platform to improve treatment retention and reduce relapse in opioid use disorder1R43DA051279-01 | GUTTMAN, JEREMY | BIOMOTIVATE, LLC, PA | $251,492 | ZDA1 |
| 2020 | Survive-OUD: AI Platform to Integrate Complex Data Sources, Predict Relapse, and Recommend Interventions for Opioid Use Disorder1R43DA052916-01 | LUECHTEFELD, THOMAS | INSILICA, LLC, MD | $251,348 | ZDA1 |
| 2020 | Neurxtem Neural Organoid Human Platform Development for Substance and Opioid Use Disorders1R44DA051281-01 | ANAND, RENE | NEURXSTEM, INC., OH | $241,742 | ZDA1 |
| 2020 | Mobile brain sensing platform for detection of opioid craving and treatment response1R43DA053072-01 | BURWELL, SCOTT | NEUROTYPE INC., MN | $235,084 | ZDA1 |
| 2020 | Development of safe and effective immunotherapeutics for treatment of opioid abuse and overdose1R43DA051296-01 | ZHOU, XICHUN | VITAN-BIOTECH, LLC, CO | $224,940 | ZDA1 |
| 2020 | Novel Therapeutic Agents to Reverse Opioid Overdose1R43DA052957-01 | LI, XINHUA | CLEAR SCIENTIFIC, LLC, MA | $224,889 | ZDA1 |
| 2020 | Reducing high school athletes' prescription opioids misuse and diversion through the Student Athlete Wellness Portal1R44DA051243-01 | CHOI, HYE JEONGHECHT, MICHAEL | REAL PREVENTION, LLC, NJ | $224,551 | ZDA1 |
| 2020 | Development of a scalable, portable device platform to help objectively monitor the treatment of substance abuse.1R43DA053012-01 | OAKLEY, DAVIDSTUBBLEFIELD, JAMES | WAVI COMPANY, CO | $221,675 | ZDA1 |
| 2020 | Discovering Therapeutic Agents for the Treatment of Opioid Use Disorder by Targeting Negative Allosteric Modulators of the mu-Opioid Receptor1R43DA050383-01A1 | ANDERSON, RICHARDSTIEGLITZ, KIMBERLY ANN | SYMMETRIC COMPUTING, INC., MA | $217,405 | ZDA1 |
| 2020 | Developing a Novel Mixed Opioid Agonist for the Treatment of OUD1R43DA053055-01 | VERSI, EBRAHIM | DMK PHARMACEUTICALS, INC., NJ | $191,062 | ZDA1 |
| 2019 | Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic1R44DA050368-01 | KLUMPP, KLAUS | RIBOSCIENCE, LLC, CA | $995,102 | ZDA1 |
| 2019 | BD2K product for enhancing phenotypic screens2R44DA050376-02 | FULLER, JENNIFER | GENECENTRIX, INC., NY | $742,912 | ZDA1 |
| 2019 | Virtual Reality as a Opioid Sparing Intervention for Acute Postoperative Pain Management2R44DA049640-02 | AYAD, SABRYMADDOX, WILLIAM TODDSUK, MICHAEL | APPLIEDVR, INC., CA | $734,714 | ZDA1 |
| 2019 | Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorders1R43DA050393-01 | MOLOKANOVA, ELENA | NEURANO BIOSCIENCE, CA | $349,999 | ZDA1 |
| 2019 | High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform1R44DA048686-01A1 | MAEDER, CELINE | CAIRN BIOSCIENCES, INC., CA | $323,750 | ZDA1 |
| 2019 | A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence1R43DA050349-01 | RUFF, MICHAEL R | CREATIVE BIO-PEPTIDES, INC., MD | $321,800 | ZDA1 |
| 2019 | Screen molecules modulating MOR trafficking with a newly developed MOR/14-3-3 bioassay.1R43DA050264-01 | EISHINGDRELO, HAIFENG | BIOINVENU CORPORATION, NJ | $321,000 | ZDA1 |
| 2019 | Remote vital sign and opioid overdose detection via a non-invasive wearable sensing patch1R43DA050344-01 | LI, JIANG | VIVALNK, INC., CA | $299,814 | ZDA1 |
| 2019 | Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose.1R43DA050397-01 | BRIONES, MARISA | BDH PHARMA, LLC, CA | $283,935 | ZDA1 |
| 2019 | NarcoBond: Opioid Targeted Biomimetic Nanosponges for Treatment of Opioid Overdose1R43DA050384-01 | ESMAELI-AZAD, BABAK | CIBOTS, INC., CA | $254,039 | ZDA1 |
| 2019 | NeoGUARD: An easy-to-use, low-cost brain monitor for objective screening and treatment of opioid-exposed infants1R43DA049620-01 | ZIKOV, TATJANA | NEUROWAVE SYSTEMS, INC., OH | $244,569 | ZDA1 |
| 2019 | Connected Pharmacy Platform to Improve Adherence to Buprenorphine-Naloxone Prescription Treatment of Opioid Use Disorder1R44DA049629-01 | LEBRUN, JEFFREYMCPHERSON, STERLING M | OPTIMIZE SYSTEMS INC, WA | $234,570 | ZDA1 |
| 2019 | Opioid-Sparing pain management for Chronic Low Back Pain patients using TMC-CP01 - A VANISH (Virtual Autonomic Neuromodulation Induced Systemic Healing) based program1R44DA049630-01 | LUCAS, GALEMAHAJAN, AMANTIEN, CELINE | TAMADE, LLC, CA | $225,000 | ZDA1 |
| 2019 | At-Home Virtual Reality Guided Imagery Intervention for Chronic Pain1R43DA049617-01 | LEWIS, BENJAMINRICHEIMER, STEVEN H | LIMBIX HEALTH, INC., CA | $225,000 | ZDA1 |
| 2019 | Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for relapse preventionin patients with Opioid Use (OUD)1R43DA049616-01 | LAWSON, WILLIAM BRADFORDNWULIA, EVARISTUS A | EVON MEDICS, LLC, MD | $225,000 | ZDA1 |
| 2019 | A Novel Workflow to Screen for Illicit Drug Exposure in Newborns1R44DA050375-01 | KENNEDY, ADAM DAVID | BAEBIES, INC., NC | $224,999 | ZDA1 |
| 2019 | Neurofeedback-EEG-VR (NEVR) System for Non-opioid Pain Therapy1R43DA050380-01 | SOUSSOU, WALID | QUASAR, INC., CA | $224,942 | ZDA1 |
| 2019 | A Project to Test The Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders1R43DA050358-01 | SCHIFFER, FREDRICTEICHER, MARTIN H | MINDLIGHT, LLC, MA | $224,907 | ZDA1 |
| 2019 | A universal approach for improving the limit of detection for fentanyl and fentanyl derivatives in urine1R43DA050338-01 | LEPENE, BENJAMIN SCOTT | CERES NANOSCIENCES, LLLP, VA | $224,750 | ZDA1 |
| 2019 | Transforming smartphones into active sonar systems to detect opioid overdose1R44DA050339-01 | MARK, NICHOLAS MAXWELL | SOUND LIFE SCIENCES, INC., WA | $223,507 | ZDA1 |
| 2019 | Non-invasive Neuromodulation Device for Decreasing Withdrawal Symptoms and Craving during Treatment of Opioid Use Disorder1R43DA049623-01 | BURNETT, DANIEL ROGERS | THERANOVA, LLC, CA | $223,176 | ZDA1 |
| 2019 | Fixed dose analgesic combination with non-opioid mechanism to prevent opioid misuse1R43DA050395-01 | GOMTSIAN, ARTOUR | SYNVENTA, LLC, AZ | $222,276 | ZDA1 |
| 2019 | Addressing Opioid Use Disorder with an External Multimodal Neuromodulation Device: Development and Clinical Evaluation of DuoTherm for Opioid-Sparing in Acute and Chronic Low Back Pain.1R44DA049631-01 | BAXTER, AMY LYNN | MMJ LABS, LLC, GA | $221,959 | ZDA1 |
| 2019 | An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder1R44DA050357-01 | HUGHES, THOMAS EQUINN, ANNE MARIE | MONTANA MOLECULAR, LLC, MT | $221,097 | ZDA1 |
| 2019 | Evaluating the Usability, Efficacy and Commercial Utility of a Digital Platform to Deliver Comprehensive Treatment for Opioid Use Disorder1R44DA050354-01 | PAPES, STEPHANIE | BOULDER CARE, INC., OR | $220,921 | ZDA1 |
| 2019 | Transcutaneous auricular neurostimulation for neonatal abstinence syndrome1R43DA050360-01 | JENKINS, DOROTHEA DENISEKHODAPARAST, NAVID | SPARK BIOMEDICAL INC, TX | $217,690 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.